Chronic Kidney Disease Drugs Market: By Drug Class, By Route of Administration, By Distribution Channel and Geography

Chronic Kidney Disease (CKD) Drugs Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Antihypertensive, ACE Inhibitors, Angiotensin-II Receptor Blockers, Beta Blockers, Calcium Channel Blockers, Diuretics, Anemia Treatment Drugs, Antihyperlipidemic Drugs Others), By Route of Administration (Oral, Parenteral Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Region

Chronic Kidney Disease (CKD) Drugs Market size was valued at US$ 15,278.1 million in 2023 and is poised to grow at a CAGR of 4.6% from 2024 to 2030.  Chronic kidney disease (CKD) is a progressive condition that affects millions globally. As kidney function declines, the body struggles to eliminate waste products and regulate fluids.  This escalating public health crisis fuels the chronic kidney disease drugs market. The advancements in diagnostic tools that facilitate early detection of CKD are crucial. This creates a demand for medications that can be introduced at the initial stages, potentially preventing further kidney damage. In addition, medications that help manage CKD by controlling blood pressure, regulating blood sugar levels, and reducing proteinuria (excess protein in urine) are in high demand. Early intervention with these drugs can significantly improve patient outcomes. Also, many governments are recognizing the growing burden of CKD and implementing initiatives to improve access to diagnosis and treatment. This includes allocating resources for essential medications, making them more affordable for patients.

Moreover, the development and availability of cost-effective CKD drugs are essential for expanding access to treatment in resource-limited settings. This ensures that patients across the economic spectrum can receive the medications they need to manage their condition. Furthermore, the rise of telemedicine and remote care models allows for improved patient access to CKD specialists and facilitates timely medication management consultations, even in geographically remote areas. However, developing and bringing new, innovative CKD drugs to market is a lengthy and expensive process. These high upfront costs often translate into higher prices for patients.

Chronic Kidney Disease (CKD) Drugs Market:
  • In July 2022, Grupo Olmos, a provider of renal care solutions, acquired renal care business of Diaverum, a renal healthcare provider, which runs in Argentina. The acquisition of renal business will strengthen the renal product portfolio of the company.
  • In March 2019, Aster Hospitals, the largest private healthcare service providers operating in numerous GCC states, launched an awareness and screening initiative to encourage the prevention of chronic kidney disease (CKD) through education, awareness, and early diagnosis.

Chronic Kidney Disease Ckd Drugs Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

4.6%

Largest Market

North America

Fastest Growing Market

Asia Pacific

Chronic Kidney Disease (CKD) Drugs Market Dynamics

A key driver for the CKD drugs market is the alarming rise in CKD prevalence worldwide. This surge is fueled by several concerning trends such as diabetes and hypertension, aging population demographics, and lifestyle factors. The growing prevalence of diabetes and hypertension, major risk factors for CKD, creates a significant patient pool requiring treatment. As these chronic conditions become more widespread, the demand for CKD drugs naturally increases. In addition, the global population is aging, and older individuals are more susceptible to developing CKD. This demographic shift translates to a heightened need for effective treatment options to manage the disease and improve quality of life. Moreover, unhealthy lifestyles, including poor diet, physical inactivity, and smoking, contribute to CKD development. As public health initiatives raise awareness about these risk factors, the need for preventative measures and early intervention with medications becomes more crucial.

Chronic Kidney Disease Ckd Drugs Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 15,278.1 million

Market CAGR

4.6%

By Drug Class

  • ACE Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • Beta Blockers
  • Calcium Channel Blockers
  • Loop Diuretics
  • Erythropoiesis Stimulating Agents (ESAs)
  • Phosphate Binders
  • Others

By Route of Administration

  • Oral
  • Subcutaneous
  • Intravenous

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Key Features of the Report

  • The chronic kidney disease (CKD) drugs market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenarios.

Download Free Sample Report

Frequently Asked Questions

The Asia Pacific is the fastest growing region in the Chronic Kidney Disease (CKD) Drugs Market

The North America is dominating the Chronic Kidney Disease (CKD) Drugs market.

The leading players in the Chronic Kidney Disease (CKD) Drugs Market are AstraZeneca, Amgen Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc., AbbVie Inc., Keryx Biopharmaceuticals, Inc., Kissei Pharmaceutical Co., Ltd., Sanofi, Pfizer and Teva Pharmaceutical Industries.

Historic years considered for the market study are 2019 to 2022, 2023 is considered as the base year for market estimation and the forecast presented from 2024 to 2030.

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Chronic Kidney Disease (CKD) Drugs Market Introduction
2.1. Global Chronic Kidney Disease (CKD) Drugs Market Taxonomy
2.2. Global Chronic Kidney Disease (CKD) Drugs Market Definitions
2.2.1. By  Drug Class
2.2.2. By Route of Administration
2.2.3. By Distribution Channel
2.2.4. By Region
3. Global Chronic Kidney Disease (CKD) Drugs Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Chronic Kidney Disease (CKD) Drugs Market Dynamic Factors - Impact Analysis
3.6. Global Chronic Kidney Disease (CKD) Drugs Market Competition Landscape
4. Global Chronic Kidney Disease (CKD) Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030
4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5. Global Chronic Kidney Disease (CKD) Drugs Market, By Drug Class, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
5.1. Antihypertensive
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. ACE Inhibitors
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Angiotensin-II Receptor Blockers
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Beta Blockers
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Calcium Channel Blockers
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Diuretics
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
5.7. Anemia Treatment Drugs
5.7.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.7.3. Market Opportunity Analysis
5.8. Antihyperlipidemic Drugs
5.8.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.8.3. Market Opportunity Analysis
5.9. Others
5.9.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.9.3. Market Opportunity Analysis
6. Global Chronic Kidney Disease (CKD) Drugs Market, By Route of Administration, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
6.1. Oral
6.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Parenteral
6.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Others
6.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
7. Global Chronic Kidney Disease (CKD) Drugs Market Forecast, By Distribution Channel, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Online Pharmacies
7.3.1. Market Analysis, 2017-2021 and Forecast, 2022-2028 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. Global Chronic Kidney Disease (CKD) Drugs Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Chronic Kidney Disease (CKD) Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2024 - 2030
9. North America Chronic Kidney Disease (CKD) Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
9.1.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1. Antihypertensive
9.1.2. ACE Inhibitors
9.1.3. Angiotensin-II Receptor Blockers
9.1.4. Beta Blockers
9.1.5. Calcium Channel Blockers
9.1.6. Diuretics
9.1.7. Anemia Treatment Drugs
9.1.8. Antihyperlipidemic Drugs
9.1.9. Others
9.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.2.1. Oral
9.2.2. Parenteral
9.2.3. Others
9.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.3.1. Hospital Pharmacies
9.3.2. Retail Pharmacies
9.3.3. Online Pharmacies
9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.4.1. USA
9.4.2. Canada
9.5. North America Chronic Kidney Disease (CKD) Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2024 - 2030
9.6. North America Chronic Kidney Disease (CKD) Drugs Market Dynamics Trends
10. Europe Chronic Kidney Disease (CKD) Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
10.1.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1. Antihypertensive
10.1.2. ACE Inhibitors
10.1.3. Angiotensin-II Receptor Blockers
10.1.4. Beta Blockers
10.1.5. Calcium Channel Blockers
10.1.6. Diuretics
10.1.7. Anemia Treatment Drugs
10.1.8. Antihyperlipidemic Drugs
10.1.9. Others
10.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.2.1. Oral
10.2.2. Parenteral
10.2.3. Others
10.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.3.1. Hospital Pharmacies
10.3.2. Retail Pharmacies
10.3.3. Online Pharmacies
10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.4.1. Germany
10.4.2. UK
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Europe Chronic Kidney Disease (CKD) Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2024 - 2030
10.6. Europe Chronic Kidney Disease (CKD) Drugs Market Dynamics Trends
11. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
11.1.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1. Antihypertensive
11.1.2. ACE Inhibitors
11.1.3. Angiotensin-II Receptor Blockers
11.1.4. Beta Blockers
11.1.5. Calcium Channel Blockers
11.1.6. Diuretics
11.1.7. Anemia Treatment Drugs
11.1.8. Antihyperlipidemic Drugs
11.1.9. Others
11.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.2.1. Oral
11.2.2. Parenteral
11.2.3. Others
11.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.3.1. Hospital Pharmacies
11.3.2. Retail Pharmacies
11.3.3. Online Pharmacies
11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
11.4.1. China
11.4.2. India
11.4.3. Japan
11.4.4. ASEAN
11.4.5. Australia & New Zealand
11.4.6. Rest of Asia-Pacific
11.5. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration , By Distribution Channel and Country, 2024 - 2030
11.6. Asia-Pacific Chronic Kidney Disease (CKD) Drugs Market Dynamics Trends
12. Latin America Chronic Kidney Disease (CKD) Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
12.1.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1. Antihypertensive
12.1.2. ACE Inhibitors
12.1.3. Angiotensin-II Receptor Blockers
12.1.4. Beta Blockers
12.1.5. Calcium Channel Blockers
12.1.6. Diuretics
12.1.7. Anemia Treatment Drugs
12.1.8. Antihyperlipidemic Drugs
12.1.9. Others
12.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.2.1. Oral
12.2.2. Parenteral
12.2.3. Others
12.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.3.1. Hospital Pharmacies
12.3.2. Retail Pharmacies
12.3.3. Online Pharmacies
12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Argentina
12.4.4. Rest of Latin America
12.5. Latin America Chronic Kidney Disease (CKD) Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration , By Distribution Channel and Country, 2024 - 2030
12.6. Latin America Chronic Kidney Disease (CKD) Drugs Market Dynamics Trends
13. Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) 
13.1.  Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1. Antihypertensive
13.1.2. ACE Inhibitors
13.1.3. Angiotensin-II Receptor Blockers
13.1.4. Beta Blockers
13.1.5. Calcium Channel Blockers
13.1.6. Diuretics
13.1.7. Anemia Treatment Drugs
13.1.8. Antihyperlipidemic Drugs
13.1.9. Others
13.2. Route of Administration Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.2.1. Oral
13.2.2. Parenteral
13.2.3. Others
13.3. Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.3.1. Hospital Pharmacies
13.3.2. Retail Pharmacies
13.3.3. Online Pharmacies
13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
13.4.1. Gulf Cooperation Council (GCC) Countries
13.4.2. Israel
13.4.3. South Africa
13.4.4. Rest of MEA
13.5. MEA Chronic Kidney Disease (CKD) Drugs Market - Opportunity Analysis Index, By Drug Class, By Route of Administration, By Distribution Channel and Country, 2024 - 2030
13.6. MEA Chronic Kidney Disease (CKD) Drugs Market Dynamics Trends
14. Competition Landscape 
14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. AbbVie, Inc.
14.2.2. Akebia Therapeutics
14.2.3. Allergan plc.
14.2.4. Amgen Inc.
14.2.5. Ardelyx, Inc.
14.2.6. AstraZeneca plc
14.2.7. F. Hoffmann-La Roche Ltd.
14.2.8. FibroGen
14.2.9. GlaxoSmithKline plc.
14.2.10. Johnson & Johnson
14.2.11. Kissei Pharmaceutical Co., Ltd.
14.2.12. Pfizer, Inc.
14.2.13. Reata Pharmaceuticals, Inc.
14.2.14. Sanofi S.A.
14.2.15. Teva Pharmaceutical Industries Ltd.
15. Research Methodology
16. Key Assumptions and Acronyms

Key Market Players

  • AbbVie, Inc.
  • Akebia Therapeutics
  • Allergan plc.
  • Amgen Inc.
  • Ardelyx, Inc.
  • AstraZeneca plc
  • Hoffmann-La Roche Ltd.
  • FibroGen
  • GlaxoSmithKline plc.
  • Johnson & Johnson
  • Kissei Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Reata Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Related Industry Reports